What is Kawasaki disease? Diagnosis and management in pediatrics

📚 What is Kawasaki Disease?

Kawasaki disease (KD), also known as mucocutaneous lymph node syndrome, is an acute, self-limited vasculitis of unknown etiology that primarily affects young children. It is a leading cause of acquired heart disease in developed countries. The inflammation targets medium-sized arteries, especially the coronary arteries, potentially leading to aneurysms.

📜 History and Background

Kawasaki disease was first described in Japan by Dr. Tomisaku Kawasaki in 1967. Initially, it was believed to be a benign condition. However, its potential to cause serious cardiac complications was soon recognized, making it a significant concern in pediatric cardiology.

🔑 Key Principles of Kawasaki Disease

The diagnosis of Kawasaki disease relies on clinical criteria, as there is no specific diagnostic test. Prompt treatment with intravenous immunoglobulin (IVIG) and aspirin is crucial to reduce the risk of cardiac complications.

🩺 Diagnostic Criteria

Diagnosis is based on the presence of fever for at least 5 days plus at least four of the following five criteria:

• 🌡️ Changes in the extremities (erythema or edema of the hands and feet, or periungual desquamation).
• 👁️ Polymorphous exanthem.
• 👄 Bilateral bulbar conjunctival injection (non-exudative).
• 👅 Changes in the lips and oral cavity (erythema, cracking, or fissuring of the lips; strawberry tongue; or oropharyngeal injection).
• 📍 Cervical lymphadenopathy (at least one lymph node >1.5 cm in diameter).

📊 Laboratory Findings

While not diagnostic, certain laboratory findings support the diagnosis:

• 🩸 Elevated ESR (erythrocyte sedimentation rate) and CRP (C-reactive protein).
• 📈 Thrombocytosis (elevated platelet count) in the subacute phase.
• 📉 Leukocytosis (elevated white blood cell count) with neutrophilia.
• 🧪 Mild anemia.

❤️ Cardiac Complications

Coronary artery aneurysms are the most serious complication of KD. Echocardiography is used to monitor coronary artery size.

• 🗓️ Initial echocardiogram: Performed at diagnosis.
• 🗓️ Follow-up echocardiogram: Performed 2-3 weeks later and again at 6-8 weeks after the onset of illness.

💊 Management

The primary goals of management are to reduce inflammation and prevent cardiac complications.

• 💉 Intravenous Immunoglobulin (IVIG): A single infusion of 2 g/kg IVIG is the first-line treatment, ideally administered within the first 10 days of illness.
• 💊 Aspirin: High-dose aspirin (80-100 mg/kg/day) is given initially for its anti-inflammatory effects, followed by low-dose aspirin (3-5 mg/kg/day) for its antiplatelet effects until coronary artery abnormalities resolve.
• 💪 Consider steroids: In IVIG-resistant cases, corticosteroids might be considered under specialist guidance.

⚠️ IVIG Resistance

Approximately 10-20% of patients do not respond to initial IVIG therapy. Risk factors for IVIG resistance include:

• 👶 Young age (<1 year).
• ♂️ Male gender.
• 📈 Elevated ALT (alanine aminotransferase) levels.
• 📉 Low albumin levels.

🧪 Management of IVIG Resistance

Options for managing IVIG resistance include:

• 🔄 Repeat IVIG infusion.
• 💪 Corticosteroids.
• 🧬 Infliximab (a TNF-alpha inhibitor).

🗓️ Long-Term Follow-Up

Patients with coronary artery aneurysms require long-term follow-up with a cardiologist.

• ❤️ Antiplatelet therapy: May be required to prevent thrombosis in aneurysms.
• 🏃 Lifestyle modifications: Encourage heart-healthy habits.

💡 Conclusion

Kawasaki disease is a significant cause of acquired heart disease in children. Early diagnosis and prompt treatment are essential to minimize the risk of cardiac complications. A multidisciplinary approach involving pediatricians, cardiologists, and other specialists is crucial for optimal patient outcomes.